CD276 and neuroblastoma: In addition, B7-H3 is the target of the monoclonal antibody 8H9 (Xu et al, 2009) that showed promising results when used in compartmental radioimmunotherapy (cRIT) in a clinical trial for CNS-relapsed high-risk neuroblastoma (Kramer et al, 2010).